TO THE EDITOR
Monoclonal 'villous' lymphocytosis (MVL) is an uncommon form of chronic lymphocytosis sustained by villous B cells that resemble closely the hairy B lymphocytes of splenic lymphoma with villous lymphocytes (SLVL) or splenic marginal zone lymphoma (SMZL).
1,2 MVL cells were found to be clonal, Blineage cells with morphological and immunophenotypic (CD5À, CD23À, CD25À, CD38À, CD11c þ ) characteristics different from hairy cell leukaemia, its variant form, prolymphocytic leukaemia, and polyclonal B-cell lymphocytosis/hairy Bcell lymphoproliferative disorders. 3 We have previously detailed the distinctive features of three adult patients (age 61-67 years, two female) with isolated MVL, 1 considering this disorder as either a preclinical phase or a purely lymphocytosic variant of SLVL/SMZL. Transition from MVL to an aggressive form of SLVL was documented in one of these patients, after a progressionfree interval of 7 years. 4 Having now extended the total followup period up to 15 years, it is possible to shed more light on the long-term course of this rare lymphoproliferative disease.
After 6 years of observation (Figure 1a ), progression to SLVL occurred in one patient, as shown by increasing splenomegaly (from the tip to 4 cm below coastal margin), associated with osteoarticular pain and the appearance of a serum M band (IgM type, 0.7 g/dl), mild anaemia (9.5 g/dl), and thrombocytopenia (89 Â 10 9 /l). The lymphocyte count exhibited a cyclical pattern (minimum and maximum: 6.9 and 24.1 Â 10 9 /l), with periods that were not well defined but apparently ranged from 6 to 9 months. Lately, the lymphocyte cycles were less well characterized, due to the reduced frequency of outpatient visits since the third to the fourth year. Once SLVL was diagnosed, treatment with low-dose oral chlorambucil was instituted. The patient, now aged 82, remains in relatively good clinical shape, nearly 15 years after the initial diagnosis of MVL. At the time of last examination, about 70% of circulating leukocytes were villous cells (Figure 1 , top panel) that retain their original immunophenotype of clonal CD11c þ , CD25À, CD23À, CD38À, and CD5À B cells.
In the other patient, a progressive decrease in the lymphocyte count was noted, starting from the fourth year of follow-up onwards ( Figure 1 , bottom panel). The lymphocyte decrease was slow, taking about 4 years to reach o4 Â 10 9 /l. Cyclical lymphocyte fluctuations were initially observed (minimum and maximum: 4.8 and 13.6 Â 10 9 /l). However, starting from the sixth year, villous cells were no longer detectable in the peripheral blood smear; the lymphocyte count was constantly o4 Â 10 9 /l, and o2 Â 10 9 /l from the 11th year. To date, after 15 total years of follow-up, there is no abnormal physical finding related to MVL or SLVL, and no morphological or immunophenotypic abnormality to support the diagnosis of a B-cell lymphoproliferative disease. In contrast, real-time quantitative Figure 1 Overview of long-term course and selected studies during 15 years of follow-up in two patients with MVL. Patient A (top panel), with evolution to SLVL; the side inset shows the predominance of villous lymphocytes in MGG-stained peripheral blood smear ( Â 1000). Patient B (bottom panel), in whom a spontaneous regression of MVL was noted; the side inset shows RQ-PCR results (0.5 mg DNA was amplified using patient-specific oligonucleotide for the junctional region, and reverse primer and probe for the constant region of the clonal IgH rearrangement found at diagnosis). The remission sample (R) remains positive at 5 Â 10
À2
, as compared to 10-fold serial dilutions (À1, À2, À3, À4) of the diagnostic sample taken 14.5 years earlier (D).
(RQ) PCR analysis 5 demonstrated the persistence of a circulating residual B-cell clone with the same IgH gene rearrangement as that detected at diagnosis (Figure 1 ). The patient serum was screened for hepatitis C virus (HCV) mRNA, and was found to be negative.
The data herein presented suggest that MVL may predate the SLVL (or SMZL) of some years, as confirmed by the clinical course of two out of the three MVL cases studied, but is also amenable to spontaneous regression. The distinctive feature of the MVL-SLVL complex appears to be an early isolated lymphocytosis, whereas splenomegaly and other lymphomalike symptoms would develop later. In SLVL, splenomegaly is almost always detectable, even without lymphocytosis. How often MVL would precede SLVL and issues of treatment and prognosis are all open questions. We have previously shown MVL cases to express adhesion molecules critical for the function of lymphocyte trafficking.
1 A peculiar expression of these receptors, as described in human SMZL, 6 may favour a bloodstream dissemination without organ involvement, and could help differentiate MVL/SLVL from primary SLVL.
Estimating the incidence of MVL is difficult. The diagnosis is primarily based on the careful examination of the peripheral blood film in any patient with a monoclonal B-cell lymphocytosis of undetermined significance, particularly if CD5À. In the French series including 100 SLVL cases, 2 14 out of 32 patients who never required therapy had an isolated lymphocytosis without splenomegaly, a condition that could match MVL. Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia Leukemia (2003) The cryptic t(5;11)(q35;p15.5) was recently identified in six cases of childhood AML (three FAB M1, two FAB M2 and one FAB M4) by fluorescence in situ hybridization (FISH) with subtelomeric probes.
2-4 Jaju et al 2 detected three cases among 36 patients (adults and children) with myeloid disorders who had been selected for having del(5q). Brown et al 3 detected two cases among 69 patients selected for having normal karyotypes. Finally, Panarello et al 4 found the t(5;11) in one of the five paediatric AML patients.
In three of the six cases with t(5;11), molecular studies have shown that this rearrangement fuses the human homologue of the Mus musculus nuclear receptor-binding SET-domain protein
